Stoneridge Investment Partners LLC Biomarin Pharmaceutical Inc Transaction History

Stoneridge Investment Partners LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	BUY	$80.93 - $108.63 $113,221 - $151,973	1,399 Added 47.55%	4,341 $449,000
Q3 2022 Oct 31, 2022	SELL	$82.16 - $96.94 $524,838 - $619,252	-6,388 Reduced 68.47%	2,942 $249,000
Q1 2022 Apr 26, 2022	BUY	$74.28 - $92.69 $693,032 - $864,797	9,330 New	9,330 $719,000
Q4 2021 Feb 02, 2022	SELL	$71.72 - $91.47 $304,164 - $387,924	-4,241 Closed	0 $0
Q3 2021 Nov 03, 2021	BUY	$74.77 - $85.47 $110,285 - $126,068	1,475 Added 53.33%	4,241 $328,000
Q2 2021 Aug 04, 2021	SELL	$75.51 - $84.79 $234,081 - $262,849	-3,100 Reduced 52.85%	2,766 $231,000
Q1 2021 Apr 30, 2021	BUY	$74.73 - $90.69 $438,366 - $531,987	5,866 New	5,866 $443,000
Q4 2020 Feb 02, 2021	SELL	$72.61 - $90.2 $207,737 - $258,062	-2,861 Closed	0 $0
Q3 2020 Oct 28, 2020	BUY	$71.87 - $131.03 $205,620 - $374,876	2,861 New	2,861 $218,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Stoneridge Investment Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Stoneridge Investment Partners LLC with notifications on news.